Published in Liver Transpl on February 01, 2010
Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib. Rare Tumors (2012) 1.12
Activity of angiogenesis inhibitors in metastatic epithelioid hemangioendothelioma: a case report. Cancer Biol Med (2012) 1.02
Bartonella vinsonii subsp. berkhoffii and Bartonella henselae as potential causes of proliferative vascular diseases in animals. Med Microbiol Immunol (2012) 0.88
Targeting VEGF-VEGFR Pathway by Sunitinib in Peripheral Primitive Neuroectodermal Tumor, Paraganglioma and Epithelioid Hemangioendothelioma: Three Case Reports. Case Rep Oncol (2013) 0.83
Diffuse hepatic epithelioid hemangioendothelioma developed in a patient with hepatitis C cirrhosis. Case Rep Transplant (2014) 0.83
Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun. Surg Today (2016) 0.81
Combination capecitabine and bevacizumab in the treatment of metastatic hepatic epithelioid hemangioendothelioma. Ther Adv Med Oncol (2015) 0.77
Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine. Organogenesis (2014) 0.75
A rare cause of right upper quadrant pain in a 17-year-old female. Case Rep Gastrointest Med (2013) 0.75
Five-year follow-up after clinical islet transplantation. Diabetes (2005) 7.86
Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology (2010) 3.54
Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care (2012) 3.20
Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology (2009) 2.51
Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes (2002) 2.36
Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes (2009) 2.31
Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl (2014) 2.25
Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes (2004) 2.22
Cell encapsulation: promise and progress. Nat Med (2003) 2.18
The tumor suppressor gene, RASSF1A, is essential for protection against inflammation -induced injury. PLoS One (2013) 2.14
The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol (2011) 2.12
Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2008) 2.04
Islet graft assessment in the Edmonton Protocol: implications for predicting long-term clinical outcome. Diabetes (2004) 1.98
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl (2004) 1.80
Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant (2007) 1.78
Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines. PLoS One (2012) 1.76
FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication. Proc Natl Acad Sci U S A (2002) 1.72
A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study. Ann Surg (2012) 1.69
Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes (2002) 1.61
Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS (2011) 1.61
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transpl Int (2009) 1.58
Complications of elective liver resections in a center with low mortality: a simple score to predict morbidity. Arch Surg (2011) 1.57
Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model. Liver Transpl (2010) 1.57
BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. J Leukoc Biol (2009) 1.53
Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes (2004) 1.46
Edmonton's islet success has indeed been replicated elsewhere. Lancet (2003) 1.45
Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a Subcutaneous Cell Pouch Device. Transplantation (2015) 1.44
Cyclosporine treatment improves cardiac function and systemic hemodynamics during resuscitation in a newborn piglet model of asphyxia: a dose-response study. Crit Care Med (2012) 1.42
HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. PLoS Pathog (2009) 1.40
Postresuscitation administration of doxycycline preserves cardiac contractile function in hypoxia-reoxygenation injury of newborn piglets*. Crit Care Med (2014) 1.40
Update on islet transplantation. Cold Spring Harb Perspect Med (2012) 1.40
The role of hepatic ischemia-reperfusion injury and liver parenchymal quality on cancer recurrence. Dig Dis Sci (2014) 1.39
Risk factors for early and late biliary complications in pediatric liver transplantation. Pediatr Transplant (2014) 1.38
Beta-score: an assessment of beta-cell function after islet transplantation. Diabetes Care (2005) 1.35
Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology (2003) 1.34
Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes (2002) 1.32
Factors influencing the loss of beta-cell mass in islet transplantation. Cell Transplant (2007) 1.27
Current status of clinical islet cell transplantation. Methods Mol Biol (2006) 1.25
Portal venous pressure changes after sequential clinical islet transplantation. Transplantation (2002) 1.24
Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. Am J Transplant (2005) 1.23
Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes (2006) 1.21
Toward development of imaging modalities for islets after transplantation: insights from the National Institutes of Health Workshop on Beta Cell Imaging. Transplantation (2004) 1.17
Enhancing the success of human islet isolation through optimization and characterization of pancreas dissociation enzyme. Am J Transplant (2007) 1.14
Estimation of pancreas weight from donor variables. Cell Transplant (2006) 1.13
Islet isolation and transplantation outcomes of pancreas preserved with University of Wisconsin solution versus two-layer method using preoxygenated perfluorocarbon. Transplantation (2006) 1.12
Histologic graft assessment after clinical islet transplantation. Transplantation (2009) 1.12
XIAP overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes (2005) 1.12
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation (2007) 1.11
Glucose regulates cyclin D2 expression in quiescent and replicating pancreatic β-cells through glycolysis and calcium channels. Endocrinology (2011) 1.11
Current status of pancreatic islet transplantation. Clin Sci (Lond) (2006) 1.11
Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation (2010) 1.10
Advances in pancreatic islet transplantation in humans. Diabetes Obes Metab (2006) 1.08
Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin-requiring type 1 diabetes subjects. Diabetes Technol Ther (2006) 1.08
Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome. PLoS One (2013) 1.07
Comparison of human islet isolation outcomes using a new mammalian tissue-free enzyme versus collagenase NB-1. Transplantation (2010) 1.06
Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse. Diabetes (2006) 1.05
Revascularization of transplanted pancreatic islets and role of the transplantation site. Clin Dev Immunol (2013) 1.04
The management of chronic viral hepatitis: a Canadian consensus conference 2004. Can J Gastroenterol (2004) 1.04
Effects of Lactobacillus helveticus on murine behavior are dependent on diet and genotype and correlate with alterations in the gut microbiome. Psychoneuroendocrinology (2013) 1.04
Impact of surgeon training on outcomes after resective hepatic surgery. Ann Surg Oncol (2008) 1.04
Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virus. PLoS One (2013) 1.03
Factors influencing the collagenase digestion phase of human islet isolation. Transplantation (2007) 1.03
Surgical aspects of human islet isolation. Islets (2010) 1.03
Circumportal pancreas and islet isolation. Surgery (2008) 1.03
Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. J Virol (2012) 1.02
Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl (2011) 1.01
Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs (2004) 1.01
Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am J Transplant (2004) 1.00
Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transpl Int (2008) 1.00
Risks and side effects of islet transplantation. Curr Diab Rep (2004) 1.00
Beta-cell transplantation for diabetes therapy. Lancet (2008) 0.99
Clinical application of a single-operator direct visualization system improves the diagnostic and therapeutic yield of endoscopic retrograde cholangiopancreatography. Can J Gastroenterol (2013) 0.99
Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation: interest of continuous glucose monitoring. Diabetes Care (2002) 0.99
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer (2004) 0.99
Adult hepatoblastoma: learning from children. J Hepatol (2012) 0.99
Technical aspects of islet preparation and transplantation. Transpl Int (2003) 0.98
Current indications for pancreas or islet transplant. Diabetes Obes Metab (2006) 0.98
Quality of life after islet transplant: impact of the number of islet infusions and metabolic outcome. Transplantation (2007) 0.98
Influence of donor age on islet isolation and transplantation outcome. Transplantation (2011) 0.97
Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes (2007) 0.97
Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers. Nat Biotechnol (2003) 0.96
Polycystic liver disease: experience at a teaching hospital. Am J Gastroenterol (2005) 0.96
Orthotopic liver transplantation in rats. J Vis Exp (2012) 0.96
Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology (2009) 0.95
Role of imaging in clinical islet transplantation. Radiographics (2010) 0.95
Development of either split tolerance or robust tolerance along with humoral tolerance to donor and third-party alloantigens in nonmyeloablative mixed chimeras. J Immunol (2008) 0.95